Why It Matters
The University of Texas M.D. Anderson Cancer Center faces an existential funding crisis demanding aggressive federal advocacy. The Trump administration has slashed nearly $2.7 billion in NIH funding while capping indirect cost reimbursement at 15%—devastating research infrastructure at major cancer centers. Congress is simultaneously pushing site-neutral Medicare payment reforms that would slash reimbursement for hospital outpatient services where M.D. Anderson delivers specialized cancer care.
By the Numbers
The University of Texas M.D. Anderson Cancer Center spent $100,000 on federal lobbying in the third quarter continuing its in-house advocacy strategy. Edward C. Miller serves as the sole registered lobbyist, having filed 28 disclosures totaling $3.335 million since January 2020.
The institution’s lobbying reflects a bet-the-house strategy: securing restored NIH funding, protecting indirect cost reimbursement rates, and shaping Medicare payment models to preserve revenue streams for academic medical centers.
This marks a strategic shift from M.D. Anderson’s earlier approach. Between 2003 and 2019, the center retained multiple external firms, including HillCo Partners ($610,000) and Timothy R. Rupli & Associates ($1.04 million).
M.D. Anderson now actively lobbies on research security, foreign influence threats, and intellectual property protection—reflecting evolving geopolitical concerns affecting biomedical research.
The Agenda
M.D. Anderson’s third quarter filing targets federal research funding security, Medicare reimbursement policy, and research security. Specific issues include NIH and NCI funding levels, executive orders on NIH indirect cost caps, Medicare reimbursements for cancer services, the Cassidy-Hassan Senate framework for hospital site-neutral payments, and clinical trial design.
Since 2019, the institution’s agenda has expanded significantly beyond traditional cancer center concerns. M.D. Anderson now actively lobbies on research security, foreign influence on federally funded research, intellectual property protection, and cybersecurity threats to healthcare providers—reflecting its evolving role in national security policy.
Broader Context
M.D. Anderson is lobbying amid a dramatic federal research funding crisis. The Trump administration has terminated over 2,370 active NIH grants totaling $4.9 billion, with nearly $1 billion in specific cancer research cuts. New NIH guidance caps indirect cost reimbursement at 15%—down from negotiated rates exceeding 50%—cutting approximately $6.5 billion from the research enterprise.
On Medicare, the Cassidy-Hassan Senate framework would reduce payments for hospital outpatient services, potentially costing providers up to $167 billion over ten years. Congressional leaders have raised concerns about foreign theft of critical cancer research, with NIH identifying intellectual property diversion as a key threat.
Between The Lines
Congressional activity presents both challenges and opportunities aligned with M.D. Anderson’s priorities. Senators Patty Murray, Rosa DeLauro, and Tammy Baldwin condemned the termination of over 2,370 active grants. Senate Democrats held hearings warning that proposed NIH cuts threaten America’s competitive edge against China.
The ROCR Value Based Program Act (H.R.2120 / S.1031) proposes a new Medicare payment model for radiation oncology, aligning with M.D. Anderson’s advocacy on value-based cancer care. The BRAIN Act includes provisions enhancing patient access to clinical trials.
Competitive Landscape
M.D. Anderson operates within a densely populated advocacy ecosystem. Major allies include the American Cancer Society Cancer Action Network, which lobbies on NIH funding and cancer care access. Other NCI-designated centers engage in parallel efforts, often coordinating through associations like the AAMC.
M.D. Anderson’s focus on research security may differentiate its advocacy from peers. However, on funding, reimbursement, and clinical trial access, the institution is embedded within a powerful coalition shaping American cancer research policy.
The Bottom Line
M.D. Anderson is intensifying federal advocacy amid significant threats to research funding and healthcare reimbursement. The institution’s lobbying expenditure reflects a combative policy environment where proposed NIH cuts and Medicare reforms directly jeopardize operations.
In-house lobbyist Edward Miller is focusing on preserving federal research grants, opposing indirect cost restrictions, and protecting cancer care reimbursement rates while advocating for emerging opportunities in early detection technology and value-based payment models.